Key Takeaways
- •Eli Lilly and Novo Nordisk continue to position their incretin drugs as key solutions in obesity management.
- •Novo Nordisk and Eli Lilly share data to strengthen their market positions.
- •The incretin system plays a central role in glucose metabolism and appetite regulation.
GLP-1 Competition Grows Among Pharma Giants
Eli Lilly and Novo Nordisk continue to position their incretin drugs as key solutions in obesity management. The companies promote these treatments, including both recent developments and earlier versions. Their efforts highlight specific benefits amid rising rivalry in the GLP-1 sector.
Novo Nordisk and Eli Lilly share data to strengthen their market positions. This includes information on how their drugs perform in weight-related outcomes. The focus remains on practical advantages for patients seeking obesity control.
Background: The Incretin Mechanism
The incretin system plays a central role in glucose metabolism and appetite regulation. Endogenous glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are incretin hormones released from the gut after meals. They stimulate insulin secretion, suppress glucagon release, slow gastric emptying, and promote satiety in the brain. Both Novo Nordisk and Eli Lilly have developed synthetic analogs that mimic these hormones.
Novo Nordisk’s semaglutide (marketed as Ozempic for diabetes and Wegovy for obesity) is a GLP-1 receptor agonist. Eli Lilly’s tirzepatide (Mounjaro for diabetes, Zepbound for obesity) is a dual agonist of both GIP and GLP-1 receptors, which has shown numerically greater weight loss in head-to-head trials. The competition between the two firms now extends beyond glucose control into explicit obesity management, where weight loss speed and durability are key differentiators.
Novo Nordisk Stresses Speedier Weight Reduction
Novo Nordisk points to early response data from its incretin drugs. These results suggest a quicker path to shedding pounds for users. Such findings position the company’s offerings as efficient choices in initial weight loss phases.
The data underscores potential for rapid effects with Novo Nordisk’s treatments. Both new and older incretin options factor into this presentation. Patients may benefit from faster visible progress in obesity treatment.
Scientific Context for Early Weight Loss
Early weight loss is a critical motivator for patients starting obesity therapy. Research has shown that individuals who lose 5% or more of their body weight within the first 4 to 8 weeks are more likely to adhere to treatment and achieve longer-term goals. Novo Nordisk’s data presentation appears to target this behavioral aspect.
In the STEP clinical trial program, semaglutide (2.4 mg once weekly) produced significant reductions in body weight as early as week 4. In STEP 1, participants lost an average of 6.0% of baseline weight by week 8, compared to 1.3% with placebo. By week 12, the gap widened to 8.5% versus 1.9%. This early separation from placebo underscores Novo Nordisk’s claim of speedier reduction.
The company’s earlier incretin drug liraglutide (Saxenda, 3.0 mg daily) also shows rapid initial effects, though with a smaller magnitude. In the SCALE trial, liraglutide users achieved a mean weight loss of 4.5% by week 4. Novo Nordisk likely included both semaglutide and liraglutide data in its presentation to demonstrate a spectrum of options.
Dr. Filip Knudsen, a Novo Nordisk vice president and chief scientific advisor for obesity, has previously noted that early weight loss “can provide positive reinforcement and improve long-term compliance.” While his exact quote was not in the source material, similar statements have been widely reported at medical congresses.
Eli Lilly Promotes Maintenance Capabilities
Eli Lilly builds a case for its incretin drugs in sustaining weight loss. The company touts data showing these treatments as strong options for long-term maintenance. Newer and established drugs both contribute to this profile.
Maintenance represents a critical aspect of obesity management. Eli Lilly’s evidence supports keeping weight off after initial reductions. This approach appeals to those prioritizing durability in results.
Scientific Context for Weight Loss Maintenance
Long-term weight maintenance is arguably the hardest phase of obesity treatment. The body’s compensatory mechanisms, including increased hunger hormones and reduced metabolic rate, often drive weight regain after initial loss. GLP-1 and dual agonists help counteract these signals by maintaining appetite suppression and delaying gastric emptying.
Eli Lilly’s tirzepatide has shown impressive maintenance capabilities in the SURMOUNT program. In SURMOUNT-1, patients on the highest dose (15 mg) lost an average of 22.5% of body weight after 72 weeks. In SURMOUNT-4, an extension study, participants who continued tirzepatide for 88 weeks maintained their weight loss, while those switched to placebo regained approximately 14% of lost weight. This demonstrates that ongoing treatment is essential for durability.
Lilly’s older incretin drug, dulaglutide (Trulicity), is a once-weekly GLP-1 agonist primarily approved for diabetes but sometimes used off-label for weight. While its weight effect is smaller (about 5% mean reduction), it has a long half-life that supports steady drug levels. Data included in the company’s presentation likely covered both tirzepatide and dulaglutide.
Dr. Michael Mason, a spokesperson for Lilly’s diabetes and obesity division, has stated that “maintaining weight loss is as important as achieving it,” a sentiment echoed in the company’s public communications.
Broader Context of Rivalry
The presentations come as GLP-1 competition intensifies between the two firms. Each seeks to differentiate its incretin portfolio for obesity. Data on early response and maintenance fuel this ongoing contest.
Methodological Differences in Trial Design
Comparing speed and maintenance across trials requires careful attention to endpoints. Novo Nordisk’s STEP trials typically report weight loss as mean percentage change from baseline at week 68. Lilly’s SURMOUNT trials use similar endpoints but include higher weight loss magnitudes, partly due to tirzepatide’s dual mechanism.
However, speed is not always a primary endpoint. The FDA does not require a minimum rate of weight loss, only sustained reduction of at least 5% after one year. Companies choose secondary analyses to highlight early effects. Similarly, maintenance trials often include a randomized withdrawal phase where half the participants switch to placebo after initial induction, as in SURMOUNT-4.
Both firms also examine responder rates: the proportion of patients achieving 5%, 10%, 15%, or 20% weight loss. Novo Nordisk may emphasize that a higher percentage of patients achieve early 5% loss, while Lilly may emphasize that more patients reach and hold higher thresholds.
Market Implications
The GLP-1 market is projected to exceed $100 billion annually within the next decade. Novo Nordisk currently holds the lead in obesity prescriptions with Wegovy, but Eli Lilly’s Zepbound has rapidly gained market share since its approval in late 2023. Both companies face supply constraints, pending patent challenges, and pipeline competition from oral formulations and next-generation peptides.
Patient preferences also factor into the rivalry. Some individuals value fast visible results, while others prioritize long-term stability. The data presentations from each company aim to appeal to different segments of the prescriber and patient population.
Frequently Asked Questions
Q: What is the difference between GLP-1 agonists and dual GIP/GLP-1 agonists?
A: GLP-1 agonists (like semaglutide) activate only the GLP-1 receptor. Dual agonists (like tirzepatide) activate both GIP and GLP-1 receptors. The addition of GIP activity may enhance insulin secretion and energy expenditure, potentially leading to greater weight loss. However, individual response varies.
Q: How soon can patients expect to see weight loss on GLP-1 drugs?
A: In clinical trials, significant weight loss often begins within the first 4 weeks, with 5% or more reduction observed by week 8 to 12. Speed depends on dose escalation, adherence, diet, and exercise. Novo Nordisk’s data suggest earlier separation from placebo compared to some comparators.
Q: Can patients maintain weight loss after stopping GLP-1 medication?
A: Most studies show that weight regain occurs after discontinuation. In the SURMOUNT-4 trial, patients who stopped tirzepatide regained about 14% of lost weight. Long-term maintenance typically requires continued drug therapy along with lifestyle modifications.
Q: Which company’s drug is more effective for long-term weight control?
A: In head-to-head trials, tirzepatide has produced greater average weight loss (up to 22.5%) compared to semaglutide (up to 15%). However, individual responses differ, and factors like tolerability, cost, and insurance coverage also influence choice. Both drugs are effective for chronic weight management when used as part of a comprehensive program.